{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-133205","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.059207+00:00","generated_at":"2026-06-16T01:13:22.915004+00:00","sec_items":["1.01","3.02","3.03","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Magenta to merge with Dianthus in reverse merger; Dianthus holders to own 78.7% of combined firm","bullets":["Dianthus stockholders will own ~78.7% of combined company; Magenta holders ~21.3%.","Concurrent $70M private placement of Dianthus shares and pre-funded warrants closing pre-merger.","Magenta holders get one CVR per share tied to net proceeds from legacy asset sales by Dec 31, 2023.","Magenta CEO and board largely replaced; 6 of 8 board members designated by Dianthus.","Termination fee of $13.3M payable by either party under specified conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-133205","json":"https://secwatch.observer/filing/0001193125-23-133205.json","markdown":"https://secwatch.observer/filing/0001193125-23-133205.md","text":"https://secwatch.observer/filing/0001193125-23-133205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523133205/0001193125-23-133205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523133205/d503643d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:13:22.915004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc55c7c82564a107137915e55ea663e499e44ab0","claim":"Dianthus Therapeutics, Inc. /DE/ entered into Agreement and Plan of Merger with Magenta Therapeutics, Inc. (effective 2023-05-02).","evidence_excerpt":"On May 2, 2023, Magenta Therapeutics, Inc., a Delaware corporation (“Magenta”), Dio Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Magenta (“Merger Sub”), and Dianthus Therapeutics, Inc., a Delaware corporation (“Dianthus”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523133205/0001193125-23-133205-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Magenta Therapeutics, Inc."},{"label":"Effective","value":"2023-05-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}